Assessing Researcher Needs for a Virtual Biobank

Draanen, Jenna van; Davidson, Pamela L.; Bour-Jordan, Hélène; Bowman-Carpio, Lee Anna; Boyle, David; Dubinett, Steven M.; Gardner, Brian; Gardner, Jachael; McFall, Courtney; Mercola, Dan; Nakazono, Terry T.; Soares, Stephanie; Stöppler, Hubert; Tempero, Margaret A.; Vandenberg, Scott; Wan, Yu‐Jui Yvonne; Dry, Sarah M.

doi:10.1089/bio.2016.0009

Cited by 21 publications

(20 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Virtual biobanks enable easy information sharing without the need to physically use biological samples, permitting sharing of medical data and allowing the development of networks for better cooperation between national and international biobanks. 18 As the world has been impacted by COVID-19, researchers across the globe must immediately have a virtual tool that will allow them to collaborate and analyze data based upon collected specimens along with the corresponding demographic data, clinical data collected from each case, and initial/follow-up XRT and CT scans.…”

Section: Methodsmentioning

confidence: 99%

“…16 Additional regulatory guidance for biobanks comes from several sources, which includes the International Society for Biological and Environmental Repositories (ISBER, 2012) guidelines, 17 the Organization for Economic Cooperation and Development (OECD) guidelines, and the NCI's Best Practices for Biospecimen Resources. 18 This review article emphasizes the urgent need for virtual biobanks to fight the COVID-19 pandemic. The article discusses key elements in establishing virtual biobanks, including regulatory, ethical, and financial elements.…”

Section: Regulatory Bodies Governing Biobanksmentioning

confidence: 99%

“…Data sharing tools can enable researchers across the globe to quickly access specimens and associated metadata stored by virtual biobanks required to accelerate research on COVID-19. 19 Virtual COVID-19 biobanks will also facilitate studies on COVID-19 that are logistics-prohibitive owing to a high risk of contamination of specimens (Figure 1).…”

Section: Regulatory Bodies Governing Biobanksmentioning

confidence: 99%

See 2 more Smart Citations

Data Sharing Solutions for Biobanks for the COVID-19 Pandemic

Paul¹,

Chatterjee²

2020

Biopreservation and Biobanking

View full text Add to dashboard Cite

The coronavirus disease 2019 (COVID-19) is a novel illness, which is not fully understood. Whether an individual has traveled outside their respective country or never left their community, COVID-19 is a highly contagious illness, which can result in high death rates. Biobanks will play a role in providing tools to examine data from those receiving treatment along with reviewing the current and long treatment outcomes associated with this novel coronavirus disease. A diverse, global network made up of laboratory scientists, clinical researchers, epidemiologists, data science teams, physicians, and so on must have a standardized, collaborative, virtual biobanking solution to share clinical expertise and evidence-based solutions. This virtual biobank must be centrally managed to ensure standardized quality assurance and quality control efforts. Virtual biobanks will eliminate the need to transport samples between two locations for a specific study, minimizing the risk of contamination. It is necessary for virtual biobanks to upload imaging data from those patients diagnosed with COVID-19. Standardized, collected information will be essential in the area of discovery and validation of disease markers as well as novel therapeutic strategies. It is essential for biobanks to collect COVID-19 specimens along with corresponding clinical and demographic data from COVID-19 diagnostic testing. Because COVID-19 is an acute respiratory illness, proper collection procedures must be in place to collect respiratory samples for biobanking purposes. A preconfigured purpose-built COVID-19 Laboratory Information Management System (LIMS) is an efficient tool to seamlessly manage a data sharing network. Data entered into LIMS will be beneficial in designing much needed clinical trials to address any unmet needs to better address clinical treatment and outcomes. The partners or entities associated with the COVID-19 data sharing network will be able to effectively communicate, view data, and images associated with their respective research interest to advance COVID-19 research and data driven, clinical care.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Regulatory Bodies Governing Biobanksmentioning

confidence: 99%

Section: Regulatory Bodies Governing Biobanksmentioning

confidence: 99%

See 1 more Smart Citation

Data Sharing Solutions for Biobanks for the COVID-19 Pandemic

Paul¹,

Chatterjee²

2020

Biopreservation and Biobanking

View full text Add to dashboard Cite

show abstract

“…11 When the biospecimen and the data integrated are dispersed in biobanks in multiple locations, virtual biobanks designed to connect biobanks through specialized software or web portals are established for broad-based sharing of research resources. 12 Disease-specific biobanks are generally developed in hospitals for epidemiological studies and focus on amassing large population of samples from persons with specific disease conditions such as AIDS, cancer, diabetes, and so on.…”

Section: Types Of Biobanks In Diabetes Researchmentioning

confidence: 99%

Biobanking for Translational Diabetes Research in India

Gangadharan

Wills

Vangala³

et al. 2020

BioResearch Open Access

View full text Add to dashboard Cite

India is declared as the diabetic capital of the world. Clinically well-annotated blood samples will advance diabetes research for better diagnostic and treatment methods. Building a disease-specific biobank with highquality peripheral blood mononuclear cells (PBMCs) and clinical follow-up data system will serve as a good platform for clinical research in diabetes. Processing and storage of high-quality biospecimen for translational research in diabetes demand the implementation of good clinical laboratory practices. ''Certification or accreditation programs'' that improve biorepository processes and frameworks are lacking in Indian context. To sustain and translate the research into clinical practice, good governance of the biobank and financial resources is required. For ethical issues related to health needs of the people and participants in the research, issues related to research process, translational research, and commercialization, data sharing should be addressed. For India to be an innovation and sustainable country Indian government is supporting translational research facilities, including biobanks. India has developed biobanks for various diseases; however, diabetes-specific research biorepository is lacking. Given the dangers of diabetic burden, India should set up a diabetes disease-specific repository learning from the global organizations and customize to the needs of Indian context. It is important to have private agencies get involved to develop biobanks and future research as there are commercial goals to translate research into practice. New technologies of specimen storing and preservation, data management, and data sharing should be adopted for developing cost-effective long-standing disease-specific population biobank in India.

show abstract

“…Biobanks veered towards disease research are often affiliated with hospitals, where there is easy access to samples representing a variety of diseases (Bevilacqua et al, 2010). Another example are the virtual biobanks, which seek to integrate epidemiological cohorts into a common pool (Schneider, 2008;Van Draanen et al, 2017).…”

Section: The Biobanking Situationmentioning

confidence: 99%

The 4 I’s of Entrepreneurship: A Study of the Entrepreneurial Perspectives behind A Failed Large-Scale Distributed Research Infrastructure

Larsson

2018

Entrepreneurship Research Journal

View full text Add to dashboard Cite

This case study investigates whether collective entrepreneurial team cognition remains consistent throughout all stage processes when setting up a large-scale, distributed research infrastructure. A new “action phase model” has been devised, known as the “4 I’s of entrepreneurship”, with each “I” elucidating the entrepreneurial rationale behind various stages of the creation process: Intention, Initiation, Implementation and Introspection. The case investigated was BBMRI.se (BioBanking and Molecular Resource Infrastructure in Sweden) – a Swedish large-scale distributed research infrastructure aimed at harmonizing biobanking standards. Managers and key personnel involved in founding and/or operating the organization were interviewed. The results showed there was agreement regarding the need for the research infrastructure, while there were disagreeing perceptions of what the organization should be doing and regarding the difficulties it had faced. These developments would ultimately lead to BBMRI.se’s demise. The homogenous mindset would begin to dissipate once the Initiation stage was reached and worsened throughout the Implementation stage. The results indicate that BBMRI.se’s managerial structure, personal ambitions and lack of transparency and communication were key contributors to its ultimate failure. The implications highlight the risk of fragmented motivations as collective entrepreneurs turn their ambition into reality, if given too much autonomy.

show abstract

Assessing Researcher Needs for a Virtual Biobank

Cited by 21 publications

References 18 publications

Data Sharing Solutions for Biobanks for the COVID-19 Pandemic

Data Sharing Solutions for Biobanks for the COVID-19 Pandemic

Biobanking for Translational Diabetes Research in India

The 4 I’s of Entrepreneurship: A Study of the Entrepreneurial Perspectives behind A Failed Large-Scale Distributed Research Infrastructure

Contact Info

Product

Resources

About